South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given Asian tiger status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS (1) See IP Multimedia Subsystem.

(2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS.  forecasts CAGR CAGR

See: Compound Annual Growth Rate
..... Click the link for more information. of 6.5% from 2010 through 2015, making Korea the fastest growing developed market for medicines in the world.

Currently ranked fourth in Asia-Pacific after Japan, China and India, but ahead of Australia drug sales at manufacturer selling prices are the equivalent of USD USD

In currencies, this is the abbreviation for the U.S. Dollar.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
..... Click the link for more information. 11 billion. If you consider that foreign innovative products did not gain access to the reimbursement system until late 1999 it is remarkable that multinational companies today hold half of the top-10 sales rankings with prescription products and in total have a 40% market share.

Modern-day Korea is trying hard to shake off its reputation for lack of transparency in reimbursement decisions and unfair business practices, with the Free Trade Agreements signed with the US and the EU cementing the internationalisation (programming) internationalisation - (i18n, globalisation, enabling, software enabling) The process and philosophy of making software portable to other locales.

For successful localisation, products must be technically and culturally neutral.
..... Click the link for more information. process.

With pricing and reimbursement there is still no denying the required processes are complex and multi-tiered, with major rule changes and new cost containment measures as a result of budget limitations announced in quick succession over recent years. Up to date and fully researched through local data-gathering and face-to-face interviews, Market Access Korea will explain it all, and give your company the power of Korean ginseng!

Subjects covered clearly but in detail include:

* The decision processes for new additions to the positive list and for price adjustments.

* Asias first reimbursement system requiring pharmacoeconomic evidence.

* Use of the new refund scheme if price negotiations break down.

* How market-based actual transaction pricing, introduced from 1 October 2010, will work and what it will mean.

* Pricing case studies.

* Generic and biosimilar pricing and its impact on original brands.

Key Topics Covered:

Executive Summary

1. Market Introduction

2. Pharmaceutical Sector

3. Introductory Pricing: Methodology

4. Health Technology Assessment

5. Introductory Pricing: Results

6. Price Revision

7. Demand-side Controls

8. Payment of Providers

9. Generics/Biosimilars

10. Distribution

11. Free Trade Agreements

For more information visit http://www.researchandmarkets.com/research/a8f474/market_access_kore

Comments

Search RSS

All rights reserved."